Panelists see the 5-year period of the Enhancing Oncology Model as reasonable; they would like see some progress toward permanent value-based payment structures.
Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates and the outgoing president of Community Oncology Alliance, sees 5 years of the EOM as a prelude to a more permanent reimbursement structure for addressing patients' social needs. Stephen Schleicher, MD, MBA, chief medical officer of Tennessee Oncology, hopes the EOM tracks progress in the ASCO Oncology Medical Home. Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, would like to see more key performance indicators added to the EOM.
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More